

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

VOLUNTARY ANNOUNCEMENT

**THE CATEGORY 3.1 TRADITIONAL CHINESE MEDICINE COMPOUND
PREPARATIONS REGULATED AS THE ANCIENT CLASSIC FORMULAE
SHAORYAO GANCAO TANG GRANULES AND TAOHE CHENGQI TANG
GRANULES APPROVED FOR MARKETING**

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Shaoyao Gancao Tang Granules and Taohe Chengqi Tang Granules, the category 3.1 traditional Chinese medicine compound preparations regulated as the ancient classic formulae, developed by subsidiaries of the Company, namely Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd. and Guangdong Yifang Pharmaceutical Co., Ltd. respectively, received Drug Approval Licenses issued by China National Medical Products Administration, being approved for marketing officially.

The formula of the Shaoyao Gancao Tang Granules originates from Treatise on Cold Pathogenic Diseases (《傷寒論》) written by Zhang Zhongjing of the Eastern Han Dynasty. Modern clinical evidence demonstrates that Shaoyao Gancao Tang has significant therapeutic effects on neck and lower back pain, gastrointestinal disorders, neurological diseases, skin diseases and other conditions.

The formula of the Taohe Chengqi Tang Granules also originates from Treatise on Cold Pathogenic Diseases. Relevant studies have proved its multiple benefits, including anti-inflammatory, anti-thrombotic, protecting neurons, and regulating immunity. It possesses definite clinical application value in the treatment of acute pelvic inflammatory disease, intestinal obstruction, type 2 diabetes mellitus, chronic prostatitis and other diseases.

During the research and development of the above products, the Group adheres to the research and development concept of “restoring a bowl of decoction”, implements full-process quality control from medicinal material selection and decoction pieces processing to extraction techniques and formulation development. Leveraging modern pharmaceutical technology, the core active components of these classical formulas have been maximally preserved. The successful transformation of the above granules not only puts the modernized inheritance of traditional formulas into practice but also greatly improves the convenience of medication for patients.

In the future, the Group will continue to promote the exploration and systematization of classical formulas, accelerate the registration and industrial implementation of innovative traditional Chinese medicine, facilitate the broader clinical application of modernized traditional Chinese medicine achievements, and contribute to safeguarding the life and health of the people.

This announcement is made by the Company on a voluntary basis to keep its shareholders and potential investors informed of the latest business development of the Group. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 11 May 2026

As at the date of this announcement, the Board comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LIU Haijian, Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.